Repayment of Convertible Security – Lind Global Macro Fund, LP

22nd September 2020 - 12:00 pm

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, stated in its announcement on 2 September 2020 that following the placing,  both Lind Global Macro Fund, LP (“Lind”) and L1 Capital Global Master Opportunities Fund (“L1”) had the right to require repayment of a portion of their convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11 June 2020.

The Company announces that Lind has requested repayment of part of its convertible security. The amount to be repaid in accordance with the terms of the convertible security deed is $1,068,762.50 leaving an amount outstanding under the Lind convertible security of $355,112.50.

L1 has not exercised its right to repayment.

Following the repayment the Company still expects to have sufficient cash resources to fund operations through the end of 2023.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


To download this announcement click here

Share this article